CLL Society Sends a Comment Letter to the Centers for Medicare and Medicaid Services Urging Continued Coverage of COVID-19 Treatments

In September 2022, CLL Society submitted comments to the Centers for Medicare & Medicaid (CMS) regarding the proposed rule intended to update Medicare payment policies under the Physician Fee Schedule. We advocated on behalf of the CLL / SLL community in support of continuing the existing policy to ensure COVID-19 monoclonal antibodies (such as Evusheld) and their administration costs under the Part B vaccine benefit continue to be covered. Even if/when COVID-19 monoclonal antibodies receive full FDA approval and/or the US Government’s Emergency Use Authorization declaration for such products is terminated.

Read our letter here.